Atrial fibrillation (AF) is the most common heart rhythm disorder in
adults and a major cause of stroke. Unfortunately, current treatments
for AF are suboptimal as they are not targeting the molecular mechanisms
underlying AF. In this regard, gene therapy is emerging as a promising
approach for mechanism-based treatment of AF. In this review, we
summarize recent advances and challenges in gene therapy for this
important cardiovascular disease.